Science Explorer Interactive view Map
Company · Täby · Sweden

Novartis (Sweden)

novartis.seROR OpenAlex
Research works
64
▲ 101% vs 2013–17
Citations
1.4k
21.9 per fractional work
Top-10% rate
9.3%
record average 16.5%
Open access
42%
world 28%

Not ranked overall: Novartis (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.14× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.55× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 1.70× its world share, 0 worksImmunology and Micro…Chemistry: 0.43× its world share, 0 worksChemistryEarth and Planetary Sciences: 0.26× its world share, 0 worksEarth and Planetary …Engineering: 0.05× its world share, 0 worksEngineeringPhysics and Astronomy: 2.70× its world share, 1 worksPhysics and AstronomyMedicine: 3.91× its world share, 12 worksMedicineEconomics, Econometrics and Finance: 2.34× its world share, 1 worksEconomics, Econometr…Social Sciences: 0.11× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.9×. Every wedge is a field page.

Which keywords describe research at Novartis (Sweden)?

By fractional works in all years, weighted toward what it does more of than the world: Treatment, Epidemiology, Diagnosis, Heart Failure, Inflammation, Cardiovascular Disease, Guidelines and Asthma.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Epidemiology9▲ 3.4×21 topics
  2. Treatment7▲ 8.2×10 topics
  3. Inflammation6▲ 4.0×21 topics
  4. Diagnosis5▲ 8.2×11 topics
  5. Heart Failure5▲ 17×5 topics
  6. Cardiovascular Disease5▲ 6.5×10 topics
  7. Guidelines4▲ 13×5 topics
  8. Quality of Life4▲ 4.2×9 topics
  9. Genetics3▲ 6.5×7 topics
  10. Asthma3▲ 37×2 topics
  11. Prognostic Factors3▲ 10×6 topics
  12. B-Type Natriuretic Peptide3▲ 100×1 topic
  13. Hospital Readmission3▲ 100×1 topic
  14. Clinical Trials3▲ 6.5×7 topics
  15. Breast Cancer2▲ 14×7 topics
  16. Risk Factors2▲ 3.7×5 topics
  17. Allergic Diseases2▲ 47×1 topic
  18. Eosinophils2▲ 47×1 topic
  19. Mutation2▲ 23×2 topics
  20. BCR-ABL2▲ 119×1 topic
  21. Imatinib2▲ 119×1 topic
  22. Management2▲ 4.0×7 topics
  23. Clinical Practice Guidelines2▲ 4.9×5 topics
  24. Cardiovascular Disease Prevention2▲ 33×2 topics
  25. Cost-effectiveness Analysis2▲ 33×1 topic
  26. Health Utility Measures2▲ 33×1 topic
  27. Survival Analysis2▲ 9.0×3 topics
  28. C-Reactive Protein2▲ 27×2 topics
  29. Metastatic Breast Cancer2▲ 35×2 topics
  30. Prognostic Markers1▲ 22×2 topics
  31. Statins1▲ 27×2 topics
  32. Autoantibodies1▲ 8.9×7 topics
  33. CDK4/6 Inhibitors1▲ 123×1 topic
  34. Echocardiography1▲ 7.6×2 topics
  35. Palbociclib1▲ 123×1 topic
  36. AML1▲ 41×1 topic
  37. Acute Myeloid Leukemia1▲ 41×1 topic
  38. COPD1▲ 30×1 topic
  39. Therapeutic Targets1▲ 8.0×3 topics
  40. spirometry1▲ 30×1 topic

Which research topics does Novartis (Sweden) publish most on?

By volume in 2022–2025: Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Heart Failure Treatment and Management and Lipoproteins and Cardiovascular Health.

Chronic Myeloid Leukemia Treatments: 1 fractional worksAcute Myeloid Leukemia Research: 1 fractional worksHeart Failure Treatment …1Heart Failure Treatment and Management: 1 fractional worksLipoproteins and Cardiov…1Lipoproteins and Cardiovascular Health: 1 fractional worksMyeloproliferative Neopl…1Myeloproliferative Neoplasms: Diagnosis and Treatment: 1 fractional worksAdvanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksHemoglobinopathies and Related Disorders: 0 fractional worksLung Cancer Treatments and Mutations: 0 fractional worksMagnetic confinement fusion research: 0 fractional worksCell Adhesion Molecules Research: 0 fractional works
HematologyCardiology and Cardiovascular MedicineSurgeryGenetics3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chronic Myeloid Leukemia Treatments Hematology 1 works
  2. 2 Acute Myeloid Leukemia Research Hematology 1 works
  3. 3 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 1 works
  4. 4 Lipoproteins and Cardiovascular Health Surgery 1 works
  5. 5 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 1 works
  6. 6 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  7. 7 Hemoglobinopathies and Related Disorders Genetics 0 works
  8. 8 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  9. 9 Magnetic confinement fusion research Nuclear and High Energy Physics 0 works
  10. 10 Cell Adhesion Molecules Research Immunology and Allergy 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available41.8%not open58.2%

World: 28% of research is openly available.

with international co-authors60.1%domestic only39.9%

World: 19% is written across borders.

How has Novartis (Sweden)'s research output changed?

Output in 2018–2022 was 101% higher than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Täby

All research institutions in Täby

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.